SCHEMBL4071989

SCHEMBL4071989

COc1cccc2cc(CN(C(C)C)S(=O)(=O)c3ccc4c(c3)OCCN4C)c(=O)[nH]c12

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.43
HSD17B10 Q99714 7/20 0.43
KDM4E B2RXH2 5/20 0.43
LMNA P02545 4/20 0.43
MAPK1 P28482 4/20 0.43
MAPT P10636 2/20 0.43
GAA P10253 2/20 0.39
GHSR Q92847 1/20 0.39
PDE10A Q9Y233 1/20 0.39
HTT P42858 2/20 0.38
RECQL P46063 1/20 0.38
TSHR P16473 1/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PTGES2 Q9H7Z7 1/20 0.36
USP2 O75604 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4069170 0.90 GHSR (0.40) ALDH1A1HSD17B10KDM4ELMNAMAPK1
SCHEMBL4075936 0.90 KDM4E (0.55) ALDH1A1HSD17B10KDM4ELMNAMAPK1
SCHEMBL5455857 0.90 ALDH1A1 (0.45) ALDH1A1HSD17B10KDM4ELMNAMAPK1
SCHEMBL4071107 0.89 ALDH1A1 (0.45) ALDH1A1HSD17B10KDM4ELMNAMAPK1
SCHEMBL4074128 0.89 ALDH1A1 (0.45) ALDH1A1HSD17B10KDM4ELMNAMAPK1
SCHEMBL5450427 0.89 ALDH1A1 (0.45) ALDH1A1HSD17B10KDM4ELMNAMAPK1
SCHEMBL4072846 0.85 KDM4E (0.46) ALDH1A1HSD17B10KDM4ELMNAMAPT
SCHEMBL4075260 0.85 HSD17B10 (0.53) ALDH1A1HSD17B10KDM4ELMNAMAPK1
SCHEMBL4072879 0.83 ALDH1A1 (0.50) ALDH1A1HSD17B10KDM4ELMNAMAPK1
SCHEMBL4073849 0.83 ALDH1A1 (0.39) ALDH1A1HSD17B10KDM4ELMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US claimed
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP disclosed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US disclosed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof ABCG2, ATP5ME, ATP5MG ALDH1A1 1055/4885HSD17B10 1580/4885KDM4E 2403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.